Given the expanding interest in the diagnostic and prognostic relevance of CA125 beyond oncology, future research should prioritize prospective, multicenter studies to validate condition-specific cutoff values in non-malignant settings such as heart failure, cardiometabolic disorders, cirrhosis, and autoimmune diseases. Here, MUC16 is linked to Cirrhosis.